Prolonged heparin after uncomplicated coronary interventions: a prospective, randomized trial.
BACKGROUND
Continuous heparin infusion after percutaneous transluminal coronary angioplasty (PTCA) procedures prolongs the hospital stay and could increase the occurrence of bleeding complications. The aim of this randomized trial was to evaluate whether omission of heparin infusion after uncomplicated coronary interventions in patients with stable and unstable angina with or without stent implantation increased the incidence of acute cardiac complications.


RESULTS
A total of 191 consecutive patients who underwent successful PTCA were randomly assigned to receive either prolonged heparin (heparin group) or no postprocedure heparin (control group). The 2 treatment groups were comparable with respect to clinical and angiographic characteristics. Stents were used in 36% of the control group and in 33% of the heparin group. Cardiac complications occurred in 8 (4%) patients. Four (4%) patients in the control group and 3 (3%) patients in the heparin group had a myocardial infarction. One patient in the control group died 3 days after the intervention. No patient in either group needed a repeat revascularization during the target hospitalization. Peripheral vascular complications in the control and heparin groups occurred in 1% and 3% of the patients, respectively.


CONCLUSIONS
Omission of heparin after successful PTCA with or without stent implantation in patients with stable and unstable angina did not significantly increase the incidence of acute cardiac complications. It allows for early sheath removal and patient discharge and saves costs. This study, combined with other small studies in the field, provides strong evidence that heparin should not be used routinely.
Garachemani
A R
AR
Department of Cardiology, University Hospital, Bern, Switzerland.
Kaufmann
U
U
Fleisch
M
M
Meier
B
B
D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000191:economics; D003327:Coronary Disease / Q000191:economics / Q000628:therapy*; D003362:Cost-Benefit Analysis; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced / Q000191:economics; D006493:Heparin / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007262:Infusions, Intravenous; D007902:Length of Stay / Q000191:economics; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D015607:Stents; D016896:Treatment Outcome
D006493:Heparin